一项评估 BLU-554 在肝细胞癌患者中安全性、耐受性、药代动力学、药效学和初步疗效的I期研究
[Translation] A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BLU-554 in Patients with Hepatocellular Carcinoma
确定BLU-554qd及bid给药时的 MTD 和推荐II期剂量(RP2D)、两种给药方案的安全性和耐受性。
[Translation] To determine the MTD and recommended Phase II dose (RP2D) of BLU-554 when administered qd and bid, and the safety and tolerability of the two dosing regimens.
100 Clinical Results associated with Catalent San Diego, Inc.
0 Patents (Medical) associated with Catalent San Diego, Inc.
100 Deals associated with Catalent San Diego, Inc.
100 Translational Medicine associated with Catalent San Diego, Inc.